Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments

Investigational New Drugs

Volumn 30, Issue 1, 2012, Pages 144-156

  Leguerney, Ingrid ^a   Lassau, Nathalie ^a   Koscielny, Serge ^a   Rodrigues, Mélanie ^a   Massard, Christophe ^a   Rouffiac, Valérie ^a   Benatsou, Baya ^a   Thalmensi, Jessie ^a   Bawa, Olivia ^a   Opolon, Paule ^a   Peronneau, Pierre ^a   Roche, Alain ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Anti angiogenic drug; DCE ultrasonography; Functional imaging; Interstitial pressure; Melanoma

Indexed keywords

BEVACIZUMAB; SORAFENIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD RHEOLOGY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EVALUATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; ECHOGRAPHY; FEMALE; IMMUNOHISTOCHEMISTRY; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PRESSURE MEASUREMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TISSUE PRESSURE; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CONTRAST MEDIA; DRUG ADMINISTRATION SCHEDULE; EXTRACELLULAR FLUID; FEMALE; FIBER OPTIC TECHNOLOGY; MELANOMA, EXPERIMENTAL; MICE; NEOVASCULARIZATION, PATHOLOGIC; PERFUSION IMAGING; PHOSPHOLIPIDS; PRESSURE; PYRIDINES; REGIONAL BLOOD FLOW; SULFUR HEXAFLUORIDE; TIME FACTORS; TRANSDUCERS, PRESSURE; ULTRASONOGRAPHY, DOPPLER;

EID: 84856548639     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9543-y     Document Type: Article

References (48)

1. Young JS, Lumsden CE, Stalker AL (1950) The significance of the tissue pressure of normal testicular and of neoplastic (Brown- Pearce carcinoma) tissue in the rabbit. J Pathol Bacteriol 62(3):313-333
2. Gullino PM, Clark SH, Grantham FH (1964) The interstitial fluid of solid tumors. Cancer Res 24:780-794
3. Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK (1991) Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 51(24):6691-6694
4. Jain RK (1988) Determinants of tumor blood flow: A review. Cancer Res 48(10):2641-2658
5. Sevick EM, Jain RK (1989) Geometric resistance to blood flow in solid tumors perfused ex vivo: Effects of tumor size and perfusion pressure. Cancer Res 49(13):3506-3512 (Pubitemid 19178166)
6. Heldin CH, Rubin K, Pietras K, Ostman A (2004) High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 4(10):806-813 (Pubitemid 39331152)
7. Jain RK (1987) Transport of molecules in the tumor interstitium: A review. Cancer Res 47(12):3039-3051 (Pubitemid 17082621)
8. Curti BD, Urba WJ, Alvord WG et al (1993) Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: Changes during treatment. Cancer Res 53(10 Suppl):2204-2207 (Pubitemid 23156799)
9. Milosevic M, Fyles A, Hedley D et al (2001) Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res 61(17):6400-6405 (Pubitemid 32783245)
10. Milosevic M, Fyles A, Hedley D, Hill R (2004) The human tumor microenvironment: Invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 14(3):249-258 (Pubitemid 38903229)
11. Jain RK (2001) Normalizing tumor vasculature with antiangiogenic therapy: A new paradigm for combination therapy. Nat Med 7(9):987-989 (Pubitemid 32937367)
12. Jain RK (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307(5706):58-62 (Pubitemid 40093472)
13. Sorensen AG, Patel S, Harmath C et al (2001) Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 19(2):551-557 (Pubitemid 32112870)
14. Lassau N, Mercier S, Koscielny S et al (1999) Prognostic value of high-frequency sonography and color Doppler sonography for the preoperative assessment of melanomas. AJR Am J Roentgenol 172(2):457-461 (Pubitemid 29082665)
15. Lassau N, Paturel-Asselin C, Guinebretiere JM et al (1999) New hemodynamic approach to angiogenesis: Color and pulsed Doppler ultrasonography. Invest Radiol 34(3):194-198 (Pubitemid 29147051)
16. Lavisse S, Lejeune P, Rouffiac V et al (2008) Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol 43(2):100-111
17. Elie N, Kaliski A, Peronneau P, Opolon P, Roche A, Lassau N (2007) Methodology for quantifying interactions between perfusion evaluated by DCE-US and hypoxia throughout tumor growth. Ultrasound Med Biol 33(4):549-560 (Pubitemid 46476828)
18. Rouffiac V, Duret JS, Peronneau P et al (2006) Combination of HIFU therapy with contrast-enhanced sonography for quantitative assessment of therapeutic efficiency on tumor grafted mice. Ultrasound Med Biol 32(5):729-740
19. Wilhelm S, Chien DS (2002) BAY 43-9006: Preclinical data. Curr Pharm Des 8(25):2255-2257 (Pubitemid 35189898)
20. Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C, Lee WM (2006) Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 169(5):1875-1885 (Pubitemid 351182016)
21. Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333(2):328-335 (Pubitemid 40848295)
22. Chang YS, Adnane J, Trail PA et al (2007) Sorafenib (BAY 43- 9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59(5):561-574 (Pubitemid 46295136)
23. Liu L, Cao Y, Chen C et al (2006) Sorafenib blocks the RAF/ MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/ 5. Cancer Res 66(24):11851-11858 (Pubitemid 46094197)
24. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099-7109 (Pubitemid 39331023)
25. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125-134 (Pubitemid 46089673)
26. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390
27. Kolinsky K, Shen BQ, Zhang YE et al (2009) In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models. Mol Cancer Ther 8(1):75-82
28. Cusack JC Jr, Liu R, Xia L et al (2006) NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin Cancer Res 12(22):6758-6764 (Pubitemid 44876845)
29. Segerstrom L, Fuchs D, Backman U, Holmquist K, Christofferson R, Azarbayjani F (2006) The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr Res 60(5):576-581 (Pubitemid 44627405)
30. Azad NS, Posadas EM, Kwitkowski VE et al (2008) Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26(22):3709-3714
31. Feldman DR, Baum MS, Ginsberg MS et al (2009) Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27(9):1432-1439
32. Lassau N, Chami L, Benatsou B, Peronneau P, Roche A (2007) Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: A new diagnostic tool to evaluate the early effects of antiangiogenic treatment. Eur Radiol 17(Suppl 6):F89-F98 (Pubitemid 351337913)
33. Miller DL, Dou C, Wiggins RC (2007) Doppler mode pulse sequences mitigate glomerular capillary hemorrhage in contrastaided diagnostic ultrasound of rat kidney. IEEE Trans Ultrason Ferroelectr Freq Control 54(9):1802-1810
34. Hagendoorn J, Tong R, Fukumura D et al (2006) Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res 66(7):3360-3364
35. Dickson PV, Hamner JB, Sims TL et al (2007) Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13(13):3942-3950 (Pubitemid 47037602)
36. Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9(6):685-693 (Pubitemid 36749217)
37. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64(11):3731-3736 (Pubitemid 38697278)
38. Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65(3):671-680 (Pubitemid 40216420)
39. Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3(1):24-40 (Pubitemid 43108832)
40. Soria JC, Sessa C, Perotti A, et al. (2008) A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors. AACR Meeting Abstracts, Apr 2008; LB-302,2008.
41. Fadnes HO, Reed RK, Aukland K (1977) Interstitial fluid pressure in rats measured with a modified wick technique. Microvasc Res 14(1):27-36 (Pubitemid 8153795)
42. Scholander PF, Hargens AR, Miller SL (1968) Negative pressure in the interstitial fluid of animals. Fluid tensions are spectacular in plants; in animals they are elusively small, but just as vital. Science 161(839):321-328
43. Wiederhielm CA, Woodbury JW, Kirk S, Rushmer RF (1964) Pulsatile pressures in the microcirculation of frog's mesentery. Am J Physiol 207:173-176
44. Rofstad EK, Tunheim SH, Mathiesen B et al (2002) Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts. Cancer Res 62(3):661-664 (Pubitemid 34126937)
45. Ozerdem U (2009) Measuring interstitial fluid pressure with fiberoptic pressure transducers. Microvasc Res 77(2):226-229
46. Gutmann R, Leunig M, Feyh J et al (1992) Interstitial hypertension in head and neck tumors in patients: Correlation with tumor size. Cancer Res 52(7):1993-1995
47. Jain RK, Baxter LT (1988) Mechanisms of heterogenous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res 48:7022-7032 (Pubitemid 19013976)
48. Boucher Y, Baxter LT, Jain RK (1990) Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: Implications for therapy. Cancer Res 50(15):4478-4484 (Pubitemid 20230379)